These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 19595686)

  • 1. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.
    Henriksen K; Byrjalsen I; Nielsen RH; Madsen AN; Larsen LK; Christiansen C; Beck-Nielsen H; Karsdal MA
    Eur J Pharmacol; 2009 Aug; 616(1-3):340-5. PubMed ID: 19595686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
    Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
    Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
    Zanchi A; Perregaux C; Maillard M; Cefai D; Nussberger J; Burnier M
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1228-34. PubMed ID: 16835400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
    Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
    Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
    Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
    Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.
    Agrawal R; Jain P; Dikshit SN
    Mini Rev Med Chem; 2012 Feb; 12(2):87-97. PubMed ID: 22372600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
    Nakagawa T; Goto H; Hussein G; Hikiami H; Shibahara N; Shimada Y
    Diabetes Res Clin Pract; 2008 Apr; 80(1):40-7. PubMed ID: 18242756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise training attenuates lipectomy-induced impaired glucose tolerance in rats.
    Coelho DF; Gualano B; Artioli GG; Roschel H; Amano M; Benatti FB; Fernandes T; Bueno CR; Câmara NO; Lancha AH
    Endocr Regul; 2009 Jul; 43(3):107-16. PubMed ID: 19817505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride.
    Schaalan M; El-Abhar HS; Barakat M; El-Denshary ES
    J Diabetes Complications; 2009; 23(3):199-208. PubMed ID: 18407527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
    Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
    Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
    J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.